Nr.Numele studiuluiStatusLocatia/Locatiile studiului
1A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)In curs de recrutareBucharest, Romania, 10825, Contact: Contact    1-888-EXELIXIS (888-393-5494)      Bucharest, Romania, 11863, Contact: Contact    1-888-EXELIXIS (888-393-5494)      Cluj-Napoca, Romania, 400058, Contact: Contact    1-888-EXELIXIS (888-393-5494)      Cluj-Napoca, RomaniaTimisoara, Romania, 300723
2A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted TherapyIn curs de recrutareExelixis Clinical Site #149, Cluj-Napoca, Cluj, Romania, 400015Exelixis Clinical Site #150, Craiova, Dolj, Romania, 200385Exelixis Clinical Site #142, Timişoara, Timis, Romania, 300166Exelixis Clinical Site #146, Bucuresti, Romania, 011863
3A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileActiv, inca nu se recruteazaFacility #1, Cluj-Napoca, Cluj, Romania, 400058Facility #1, Bucharest, Romania, 11863
4An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerActiv, inca nu se recruteazaInvestigational Site Number 1801, Bucharest, Romania
(Visited 2 times, 1 visits today)